Reuschenbach et al. [47] evaluated the safety and immunogenicity of vaccine P16_37-63, combined with Montanide ISA-51 VG, in 26 patients with advanced cancer and HPV-positive with overexpression of p16INK4a, as determined by immunohistochemistry (Table 3). This evidence concerns the gene CDKN2A and cancer.